Anti-PEG antibodies in drug delivery: From origins to mitigation strategies
Advanced Drug Delivery Reviews · 2027-01 · 240 · 115984
DOI: 10.1016/j.addr.2026.115984 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advanced Drug Delivery Reviews, 2027-01. Verfasst von Tianhao Ding und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, School of Basic Medical Sciences and Department of Pharmacy, Shanghai Pudong Hospital, Fudan University, Shanghai 200032,…. Die Arbeit nennt 202 Literaturangaben. Gefördert von: Shanghai Municipal Education Commission, National Natural Science Foundation of China, China Postdoctoral Science Foundation.
Abstract (Originalsprache)
Poly(ethylene glycol) (PEG) is a cornerstone excipient in drug delivery, widely used to prolong circulation duration and improve the therapeutic efficacy of protein therapeutics and nanomedicines. However, both pre-existing and treatment-induced anti-PEG antibodies have been increasingly recognized during clinical applications, raising concerns regarding the safety, efficacy, and translational reliability of PEGylated therapeutics. In this review, we summarize the origins and prevalence of anti-PEG antibodies, critically evaluate current detection methodologies, and analyze antibody-PEG binding patterns and downstream biological effects, including complement activation, accelerated blood clearance, hypersensitivity reactions, and tissue-specific toxicities, while emphasizing the context-dependent impact of anti-PEG immunity on therapeutic efficacy. We also discuss the emerging strategies to mitigate anti-PEG-mediated risks and outline the key challenges and future directions. This integrated framework aims to facilitate functional interpretation of anti-PEG immunity and support the rational design and clinical translation of next-generation PEGylated drug delivery systems.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacology, School of Basic Medical Sciences and Department of Pharmacy, Shanghai Pudong Hospital, Fudan University, Shanghai 200032, PR China.
- Department of Pharmacy, Huashan Hospital, Fudan University, Shanghai 200032, PR China.
- Department of Pharmacology, School of Basic Medical Sciences and Department of Pharmacy, Shanghai Pudong Hospital, Fudan University, Shanghai 200032, PR China. Electronic address: cyzhan@fudan.edu.cn.
Förderung
- Shanghai Municipal Education Commission
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
Zitieren
APA
Ding, T., Fu, J., Zhao, X., Lu, H., & Zhan, C. (2027). Anti-PEG antibodies in drug delivery: From origins to mitigation strategies. Advanced Drug Delivery Reviews, 240, 115984. https://doi.org/10.1016/j.addr.2026.115984
Vancouver
Ding T, Fu J, Zhao X, Lu H, Zhan C. Anti-PEG antibodies in drug delivery: From origins to mitigation strategies. Advanced Drug Delivery Reviews. 2027;240:115984. doi:10.1016/j.addr.2026.115984
BibTeX
@article{Ding2027,
author = {Ding, Tianhao and Fu, Jiaru and Zhao, Xinyue and Lu, Huiping and Zhan, Changyou},
title = {Anti-PEG antibodies in drug delivery: From origins to mitigation strategies},
journal = {Advanced Drug Delivery Reviews},
year = {2027},
volume = {240},
pages = {115984},
doi = {10.1016/j.addr.2026.115984}
}
EUVIMED